Literature DB >> 16316624

Interaction of myocilin with the C-terminal region of hevin.

Yanxia Li1, J Daniel Aroca-Aguilar, Sikha Ghosh, Francisco Sánchez-Sánchez, Julio Escribano, Miguel Coca-Prados.   

Abstract

Myocilin, a matricellular protein, is mutated in glaucoma. Here we report the identification and characterization, by the yeast two-hybrid system, of a putative interacting protein with myocilin. One of the positive clones exhibited 100% identity with the carboxyl-terminal (C-t) region of hevin, a member of the BM-40/SPARC/osteonectin family of extracellular matrix proteins. Protein interaction was assayed, in doubly transfected 293-T cells, by Western blot and fluorescent microscopy. Western blot analysis of the culture medium and lysates from cotransfected cells indicated that myocilin causes intracellular accumulation of hevin-C-t and impairs its secretion. This effect on hevin-C-t was augmented when coexpressed with the myocilin P370L mutant, known to cause a severe form of glaucoma. By fluorescent microscopy, myocilin localizes with hevin-C-t in the Golgi in cotransfected 293-T cells and with hevin-wt in the ocular ciliary epithelium. Overall, these results suggested that the C-t of hevin contains important determinants for interaction with myocilin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16316624     DOI: 10.1016/j.bbrc.2005.11.082

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Interaction of recombinant myocilin with the matricellular protein SPARC: functional implications.

Authors:  José-Daniel Aroca-Aguilar; Francisco Sánchez-Sánchez; Sikha Ghosh; Ana Fernández-Navarro; Miguel Coca-Prados; Julio Escribano
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

2.  Characterization of monoclonal antibodies against the glaucoma-associated protein myocilin.

Authors:  Mohamed-Karim Ezzat; Kyle G Howell; Cindy K Bahler; Thomas G Beito; Nils Loewen; Eric M Poeschla; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-07-12       Impact factor: 3.467

Review 3.  Glaucoma-associated myocilin: a better understanding but much more to learn.

Authors:  Zachary T Resch; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-08-29       Impact factor: 3.467

4.  Effect of hevin deletion in mice and characterization in trabecular meshwork.

Authors:  Min Hyung Kang; Dong-Jin Oh; Douglas J Rhee
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-06       Impact factor: 4.799

5.  Expression of myocilin mutants sensitizes cells to oxidative stress-induced apoptosis: implication for glaucoma pathogenesis.

Authors:  Myung Kuk Joe; Stanislav I Tomarev
Journal:  Am J Pathol       Date:  2010-04-09       Impact factor: 4.307

6.  Expression profile of the matricellular protein osteopontin in primary open-angle glaucoma and the normal human eye.

Authors:  Uttio Roy Chowdhury; Seung-Youn Jea; Dong-Jin Oh; Douglas J Rhee; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-16       Impact factor: 4.799

Review 7.  Matricellular proteins in the trabecular meshwork: review and update.

Authors:  Ayan Chatterjee; Guadalupe Villarreal; Douglas J Rhee
Journal:  J Ocul Pharmacol Ther       Date:  2014-06-05       Impact factor: 2.671

8.  Myocilin is a modulator of Wnt signaling.

Authors:  Heung-Sun Kwon; Hee-Sheung Lee; Yun Ji; Jeffrey S Rubin; Stanislav I Tomarev
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

9.  Functional role of proteolytic processing of recombinant myocilin in self-aggregation.

Authors:  José-Daniel Aroca-Aguilar; Francisco Martínez-Redondo; Francisco Sánchez-Sánchez; Miguel Coca-Prados; Julio Escribano
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

10.  Elevated amounts of myocilin in the aqueous humor of transgenic mice cause significant changes in ocular gene expression.

Authors:  Walter Paper; Markus Kroeber; Sebastian Heersink; Dietrich A Stephan; Rudolf Fuchshofer; Paul Russell; Ernst R Tamm
Journal:  Exp Eye Res       Date:  2008-06-17       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.